36 results about "Anti-Rabies virus IgG" patented technology

The invention discloses an anti-rabies virus monoclonal antibody and a preparation method and an application, belonging to the field of biomedicine and particularly relating to the preparation of a monoclonal antibody capable of identifying rabies virus and the application. The monoclonal antibody of the invention is screened by indirect Enzyme-linked immunosorbent assay (ELISA), and specificity and affinity thereof combined with antigen are identified by methods such as polyacrylamide gel electrophoresis analysis, speckle ELISA, immunoblot analysis and the like. The anti-rabies virus monoclonal antibody of the invention can be applied in multiple testing methods of antigen of rabies virus and can be also applied in the preparation of rabies virus detecting kit. The anti-rabies virus monoclonal antibody is secreted by anti-rabies virus monoclonal antibody hybridoma cell strain 2C5 with the preservation number being CGMCC No.3014.

This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies administered through OM, SAS, IVB, IV, and IA routes. An embodiment provides devices for intranasal delivery of therapeutic agents to olfactory mucosal area. Another embodiment uses the technology to deliver the therapeutic, pharmaceutical, biochemical, and biological agents or compounds to the subarachnoid space and ventricular system by using continuous catheters and Ommaya reservoir at the same time. The present method incorporates breaking the blood brain barrier to allow the entry of the anti rabies therapeutic agents into the neuropile. Additionally, an embodiment incorporates cooling of the brain and inducing hibernation to preserve the brain from damage due to rabies.

The invention aims at providing a rabies virus resistant neutralizing antibody, and particularly provides a humanized or completely humanized monoclonal antibody to meet the requirement for clinically diagnosing and/or treating rabies. A phage antibody library is prepared by adopting a phage antibody library technology and taking 32 parts of high-potency healthy human peripheral blood inoculated with rabies vaccines as a raw material; 7 ELISA positive antibodies are obtained through three rounds of screening from the phage antibody library; and furthermore, the neutralizing activity of the 7 ELISA positive antibodies is measured through an RFFIT method, wherein four ELISA positive antibodies, namely R5, R7, R8 and R9, have higher neutralizing activity in all. The rabies virus resistant neutralizing antibody with high affinity, which is provided by the invention, can be used for substituting ERIG and HRIG to carry out active and/or passive immune therapy on rabies virus seriously-exposed persons.

The invention relates to an anti-rabies virus IgG antibody colloidal gold immunochromatographic assay reagent plate and a preparation method. Glass fiber paper and cellulose nitrate films are laid on a polyethylene plate and a polyvinyl chloride substrate film; the cellulose nitrate film is coated with an assay line and a contrast line; and a gold-labeled probe polyester film is adhered on the assay line side; water-absorbing filter paper is adhered on the contrast line side, wherein the assay line is coated with rabies virus purified antigen, and the contrast line is coated with anti-SPA purified antigen. The reagent plate of the invention has the advantages of rapid detection, high detection accuracy, high specificity, convenient carrying, simple and convenient operation and can be usedfor detecting rabies virus antibodies of various animals and human. The assay reagent plate can be stored at the normal temperature for 1 year without special equipment or apparatus and has high assay repeatability.

The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies.

The invention discloses a recombinant rabies virus rHEP-Flury(dG-VP2) carrying two genes G and a gene VP2. According to the recombinant virus, a rabies virus HEP-Flury strain serves as a framework, the VP2 gene shown as SEQ ID NO.1 is inserted into HEP-Flury, an additional gene G of the rabies virus is inserted, and the recombinant plasmid pHEP-Flury(dG-VP2) carrying the two genes G and the gene VP2 is obtained; finally, rescuing screening is carried out, and the recombinant rabies virus rHEP-Flury(dG-VP2) is obtained. The recombinant rabies virus rHEP-Flury(dG-VP2) carries the two genes G and expresses VP2 protein, a high rabies virus resisting antibody and canine parvovirus VP2 resisting antibody level can be generated through immune induction, the cost of vaccines for dogs can be reduced, and very good application and popularization prospects are achieved.

A novel chimeric protein of rabies virus designed to express a chimeric G protein at a high level in transgenic plants. A gene was also designed and chemically synthesised to encode the chimeric G protein and expressed at high level in plant tissue. The gene was expressed in transgenic tobacco plants to examine its therapeutic efficacy against infection by rabies virus. The chimeric G protein was enriched in plant membranes. The BalbC mice were immunised with the plant leaf expressed G-protein. Plant derived chimeric G protein elicited higher immune response as compared to the commercial vaccine. The mice displayed protective immunity when they were challenged with live virus. Chimeric G protein expressed at high level in plant leaves was demonstrated to function as a commercially valuable subunit vaccine against rabies virus infection.

The invention discloses a fully-humanized rabies virus resisting neutralizing antibody. DNA sequences for encoding the antibody and binding fragments thereof, host cells containing DNA, and an expression vector are included. The invention further discloses a preparation method of the fully-humanized rabies virus resisting neutralizing antibody with high affinity and application of the antibody in medicine for treating and/or preventing rabies.

The invention discloses recombinant rabies viruses BNSP-CDV-F and BNSP-CDV-H in which canine distemper virus main immune genes are embedded. The recombinant viruses take a rabies virus strain SAD-B19as a framework, CDV-F and CDV-H genes shown in SEQ ID NO.1 and SEQ ID NO.2 are separately inserted between an N gene and P gene of a recombinant plasmid SAD-19 full-length cDNA, and finally recombinant rabies virus strains BNSP-CDV-F and BNSP-CDV-H are saved through a reverse genetic operation technology. The recombinant viruses BNSP-CDV-F and BNSP-CDV-H can express fusion protein and hemagglutinin protein of canine distemper viruses; after a vaccine prepared by mixing the recombinant viruses is used for immunizing animals, a great number of anti-rabies virus antibodies and main immune gene antibodies resistant to the canine distemper viruses can be induced and generated. The cost of the vaccine can also be reduced, and the recombinant viruses BNSP-CDV-F and BNSP-CDV-H have a good application and popularization prospect.

The invention relates to a novel rabies virus fake virus system as well as preparation and application thereof, belonging to the field of biotechnology. The novel rabies virus fake virus system comprises a carrier system and host cells, wherein the carrier system consists of pVRC-RVG series shuttle plasmids and auxiliary plasmids of a rabies virus glucoprotein gene; and when the shuttle plasmids and auxiliary plasmids in the carrier system are transfected to the host cells together, rabies virus fake viruses can be obtained from culture supernatant. The novel rabies virus fake virus system can be used for evaluating neutralizing antibodies of rabies viruses, screening neutral monoclonal antibody epitopes of the rabies viruses, carrying out high throughput screening on rabies virus medicaments, and preparing a novel rabies vaccine, so that the novel rabies virus fake virus system is a brand-new technical system for construction, preparation and application of rabies virus fake viruses.

The invention provides a recombinant rabies virus of a chimeric canine parvovirus VP2 gene, and belongs to the technical field of immunology. The recombinant rabies virus takes a rabies vaccine candidate strain SAD-B19 as a skeleton, and the VP2 gene of a CPV-2a strain currently popular in China is inserted into an SAD-B19 genome; the recombinant rabies virus strain of the chimeric VP2 protein is obtained through rescue, after immunization, high-level anti-rabies virus antibodies and anti-canine parvovirus VP2 antibodies can be induced to be generated, and the vaccine is low in cost, safe and effective.

The invention discloses rabies virus antibody test paper and a preparation method thereof and a detection method thereof, which belong to the technical field of antibody test paper. The problems of false positive risk and safety hazard in the prior art are solved. The test paper comprises, from one end to the other end, a sample pad which coats a rabies virus antigen, a gold standard pad which coats a monoclonal antibody against the rabies virus antigen, a nitrocellulose membrane which coats a detection line and a quality control line, and an absorbent pad, wherein the sample pad, the gold standard pad, the nitrocellulose membrane and the absorbent pad overlap each other and are attached to the upper surface of a backboard. The rabies virus antigen coated by the sample pad is rabies virus-like particles. According to the invention, the used labeled antigen is the rabies virus-like particles expressed by insect cells, which avoids false positives; the monoclonal antibody against the rabies virus G protein competes with a neutralizing antibody in the blood to improve the detection accuracy and sensitivity; the virus-like particles are free of nucleic acid components; and biosafety risks produced by the use of whole viruses as marker antigens are eliminated.

The invention provides an anti-rabies virus G protein scFv20 antibody and application thereof. A light chain amino acid sequence is shown as SEQ ID NO.1, and a heavy chain amino acid sequence is shownas SEQ ID NO.2. According to the invention, a phage antibody library technology is applied, 130 cases of peripheral blood lymphocytes of healthy volunteers immunized by rabies vaccines are used to construct a fully humanized anti-rabies virus scFv phage antibody library, and purified RVG protein is used as an antigen to enrich and screen the phage antibody library to obtain a strain of fully humanized anti-RVG protein scFv with neutralizing activity, named scFv20; wherein the neutralization titer is determined to be 0.5 IU/mg.

The invention relates to the technical field of biomedical engineering, and discloses a method for screening and verifying anti rabies virus neutralizing antibodies from a phage antibody library. Themethod includes the steps that A, a monoclonal phage antibody is cultured, and a culture supernatant is taken; B, qualitative analysis is performed, specifically, the culture supernatant in the step Ais placed in a 96-well plate, and co-incubated with a diluted FITC labeled anti rabies virus nucleoprotein antibody after neutralization with a DMEM medium and neutralizing viruses, BSR cell suspension culture and precooled acetone fixation sequentially, clone sequencing that can significantly inhibit virus infection is selected, repeated sequences are eliminated, and anti rabies virus antibody sequences with different neutralization activities are acquired preliminarily; C, quantitative analysis is performed, specifically, different sequences with neutralization activities are selected, phage antibody particles are prepared, purified and diluted for a certain number of times, and then the neutralization activity in vitro is determined by a RFFIT method; and D, the transient expression and activity analysis of a whole molecule antibody are further performed.

The present invention discloses preparation process of rabies virus resisting recombinant immunotoxin. The preparation process includes screening out hybridoma strain capable of generating specific rabies virus resisting monoclonal antibody, extracting hybridoma genome, amplifying antibody variable heavy chain region gene and variable light chain region gene in a PCR process, constituting rabies virus resisting neutral single chain antibody, cleaving the single chain antibody and inserting into expression vector containing Bacillus pyocyaneus exotoxin, transforming colibacillus for prokaryotic express, and purifying the expressed fusion protein. The present invention can neutralize free virus and kill virus infected cell by means of PE cytotoxicity, and may be used in the emergency prevention and treatment of rabies. The present invention is superior to chemically prepared immunotoxin, which has the demerits of low yield, large molecule, great immunogenicity, etc.